IONIS-FB-LRx
- Generic Name
- IONIS-FB-LRx
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04014335
- Locations
- 🇸🇬
IONIS Investigative Site, Singapore, Singapore
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Geographic AtrophyMacular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03815825
- Locations
- 🇪🇸
IONIS Investigative Site, Zaragoza, Spain
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Phase 2
Withdrawn
- Conditions
- Geographic AtrophyAge Related Macular Degeneration
- Interventions
- Drug: Placebo (sterline saline 0.9%)
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT03446144
- Locations
- 🇦🇺
Sydney Retina Clinic Day Surgery, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Lions Eye Institute, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath